Stock Analysis
AxoGen, Inc. (AXGN) Stock Analysis
AxoGen, Inc. (AXGN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
AxoGen, Inc. (AXGN) currently has an AIQ Score of 65/100, indicating a bullish setup. Momentum is the strongest factor at 82/100. Value is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
AXGN at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $56.95 |
| AIQ Score | 65/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $3.09B |
| P/E Ratio (TTM) | -85.18 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $0.04 |
| Revenue (Q3 FY2026) | $75.83M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.09 |
| Volume | 2.11M |
| 52-week range | $23.00-$59.72 |
| RSI 14 | 69.94 |
| 50-Day SMA | $43.27 |
| 200-Day SMA | $40.53 |
| Analyst Price Target | $58.13 |
| Next Earnings | Feb 23, 2027 |
AXGNAxoGen, Inc.
Healthcare / Medical - Devices
Absolute Strength
Above Peers
Latest quote
- Momentum82
- Value33
- Quality70
- Risk resilience55
- Sentiment—
AXGN Stock Analysis Summary
AxoGen, Inc. (AXGN) currently has an AIQ Score of 65/100, indicating a bullish setup. Momentum is the strongest factor at 82/100. Value is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, AXGN has AIQ Score of 65/100 with Momentum base of 82/100 and fading Value at 33/100. Wait for component alignment before adding exposure.
Momentum (82/100) leads while Value (33/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 2.85% stock move · AXGN classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is AXGN Bullish or Bearish Right Now?
AXGN currently has a bullish overall setup. Momentum is the strongest factor at 82/100, while Value is weakest at 33/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 70/100.
- - Momentum is constructive at 82/100.
- - Price is +29.27% above its 50-day SMA.
- - Analyst target implies +2.06% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (37 vs 5).
- - Value is the current constraint at 33/100.
Current Consensus
AXGN's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 4 neutral, and 5 sell votes. AXGN's 14-day RSI is 69.94, which places the stock in a constructive momentum range. AXGN's beta is 1.09, indicating market sensitivity broadly in line with the market.
What Changed in AXGN?
The largest recent change in AXGN is Momentum moving up by 7.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the AXGN Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
AXGN Decision Framework
Public evidence layers, setup checks, and risk context for AxoGen, Inc..
AxoGen, Inc. (AXGN) Stock Analysis
AxoGen, Inc. has an AIQ Score of 65/100 in a Bullish regime. Momentum is strongest at 82/100. Beta is 1.09, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | AXGN is in a Bullish AIQ regime with score 65/100. |
| Signal Conflict | The primary conflict is that momentum leads at 82/100 while value lags at 33/100. |
| Factor Evidence | Momentum 82/100 · Value 33/100 · Quality 70/100 · Risk 55/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 82/100.
Momentum is 82/100 and RSI (14) is 69.9.
AXGN is in a Bullish regime at 65/100.
Risk factor is 55/100 with beta 1.09 and annual volatility 61.27%.
Current conflict: momentum leads at 82/100 while value lags at 33/100.
AXGN Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
AXGN Fundamentals
AXGN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
AXGN Technical Analysis
AXGN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
AXGN Stock Catalysts
Track AXGN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
AXGN Dividend Analysis
AXGN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
AXGN Financial Data
AXGN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
AXGN Risk Analysis
AXGN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
AXGN Stock News
AXGN stock news, market tone, recent headlines, and catalyst context.
AXGN vs Medical - Devices Peers
Current peer cohort: AXGN · BBNX · BFLY · BIO · BRKR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| AXGN Current stock | 65/100 | 33/100 | 82/100 | 55/100 | 1.61 | 61.27% | Current |
| BBNX Beta Bionics, Inc. | 54/100 | 39/100 | 72/100 | 36/100 | -0.16 | 84.66% | AXGN vs BBNX |
| BFLY Butterfly Network, Inc. | 47/100 | 29/100 | 63/100 | 32/100 | 1.4 | 121.33% | AXGN vs BFLY |
| BIO Bio-Rad Laboratories, Inc. | 73/100 | 80/100 | 79/100 | 74/100 | 0.47 | 36.18% | AXGN vs BIO |
| BRKR Bruker Corporation | 64/100 | 53/100 | 83/100 | 44/100 | 0.89 | 59.79% | AXGN vs BRKR |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for AXGN: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 19, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching AXGN
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for AXGN
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
AXGN Stock FAQ
What is AXGN stock price today?
AxoGen, Inc.'s current stock price is $56.95. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is AXGN bullish or bearish right now?
AXGN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is AXGN's market cap?
AXGN's market cap is $3.09B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is AXGN's current P/E ratio?
AXGN's current P/E ratio is -85.18 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is AXGN's RSI?
AXGN's 14-day RSI is 69.94 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is AXGN above its 50-day and 200-day moving averages?
AXGN is 29.27% from its 50-day SMA and 38.00% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is AXGN's next earnings date?
AXGN's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does AXGN pay a dividend?
AXGN's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.